Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Stewart

Showing results (1121-1130 of 1,171) with videos related to

Pageof 118
Sort By:
Nature Genetics|February 10, 2015
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing lossHeng Xu, Giles W Robinson, Jie Huang, et al.
The Journal of Clinical Endocrinology and Metabolism|November 22, 2020
USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive TumorsAndrew V Uzilov, Patricia Taik, Khadeen C Cheesman, et al.
International Journal of Cancer|June 21, 2017
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapyFariba Navid, Victor M Santana, Michael Neel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2018
Establishing a Preclinical Multidisciplinary Board for Brain TumorsBirgit V Nimmervoll, Nidal Boulos, Brandon Bianski, et al.
Neuro-Oncology|April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2020
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignanciesSara M Federico, Alberto S Pappo, Natasha Sahr, et al.
Neuro-Oncology|March 25, 2017
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) studyAnuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, et al.
Cancer Research|November 16, 2014
Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cellsAnna E Vilgelm, Jeff S Pawlikowski, Yan Liu, et al.
Neuro-Oncology|January 14, 2014
Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastomaJames G Gurney, Johnnie K Bass, Arzu Onar-Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancerA D Seidman, A Brufsky, R H Ansari, et al.
Pageof 118

Showing results (1121-1130 of 1,171) with videos related to

Sort By:
Pageof 118
Nature Genetics|February 10, 2015
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing lossHeng Xu, Giles W Robinson, Jie Huang, et al.
The Journal of Clinical Endocrinology and Metabolism|November 22, 2020
USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive TumorsAndrew V Uzilov, Patricia Taik, Khadeen C Cheesman, et al.
International Journal of Cancer|June 21, 2017
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapyFariba Navid, Victor M Santana, Michael Neel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2018
Establishing a Preclinical Multidisciplinary Board for Brain TumorsBirgit V Nimmervoll, Nidal Boulos, Brandon Bianski, et al.
Neuro-Oncology|April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2020
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignanciesSara M Federico, Alberto S Pappo, Natasha Sahr, et al.
Neuro-Oncology|March 25, 2017
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) studyAnuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, et al.
Cancer Research|November 16, 2014
Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cellsAnna E Vilgelm, Jeff S Pawlikowski, Yan Liu, et al.
Neuro-Oncology|January 14, 2014
Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastomaJames G Gurney, Johnnie K Bass, Arzu Onar-Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancerA D Seidman, A Brufsky, R H Ansari, et al.
Pageof 118